Millie
your market intelligence analyst
Search Results
21 results
Your search is now limited to «Early Detection» expert search.
Your search is now limited to only one Source. To return to results from all sources click here.
Business Wire 08/01/2019 16:05
Through the deep interrogation and analysis of approximately 20,000 genes in both DNA and RNA, ImmunoID NeXT consolidates multiple biomarker assays into one, providing a multidimensional view of the tumor- and immune-related components of the tumor microenvironment from a single sample.
Business Wire 07/16/2019 08:00
The study of 993 patients with 245 malignancies shows that Vermillion’s second generation multivariate index assay, Overa® (MIA2G), had superior sensitivity to the current standards of care, Risk of Malignancy Algorithm (ROMA) and CA125, in detecting ovarian cancer, and the lowest false-negative rate in correctly characterizing ovarian malignancy risk.
Business Wire 06/20/2019 16:35
About the clonoSEQ Assay The clonoSEQ assay was granted de novo designation and marketing authorization by FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) using DNA from bone marrow samples.
Business Wire 06/03/2019 08:00
PathMAP Functional Signaling Profiles are made possible by the Company’s proprietary SnapPath® Cancer Diagnostics System, which was developed specifically to enable predictive tests to guide targeted drug development and treatment selection for patients with solid tumor cancers.
Business Wire 06/03/2019 02:00
Biomarker research is critical to informing the development of new immunotherapy agents, particularly in difficult-to-treat cancers like uveal melanoma,” said Mark R Middleton, MD, lead study investigator and Head of the Department of Oncology at the University of Oxford ...
Business Wire 05/30/2019 06:30
In a retrospective study of multiple cancer types published in Science in 2018, CancerSEEK was shown to perform with greater than 99% specificity and with sensitivities ranging from 69% to 98% for the detection of five cancer types – ovarian, liver, stomach, pancreas and esophageal – for which there are no screening tests available for average-risk individuals ...

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications